Scorpius Holdings (Scorpius Holdings) Cash-to-Debt : 0.17 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Scorpius Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.17.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Scorpius Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Scorpius Holdings's Cash-to-Debt or its related term are showing as below:

SCPX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 28.83 Max: No Debt
Current: 0.17

During the past 13 years, Scorpius Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.17. And the median was 28.83.

SCPX's Cash-to-Debt is ranked worse than
92.43% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs SCPX: 0.17

Scorpius Holdings Cash-to-Debt Historical Data

The historical data trend for Scorpius Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Scorpius Holdings Cash-to-Debt Chart

Scorpius Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

7.65

60.45

50.02

4.20

0.17

Scorpius Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															4.20	3.15	1.65	0.47	0.17

Competitive Comparison of Scorpius Holdings's Cash-to-Debt

For the Biotechnology subindustry, Scorpius Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scorpius Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Cash-to-Debt falls into.

Scorpius Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Scorpius Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.391	/	(1.429	+	12.613)
	=	0.17

Scorpius Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.391	/	(1.429	+	12.613)
	=	0.17

Scorpius Holdings (AMEX:SCPX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Scorpius Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Scorpius Holdings (Scorpius Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

1HB:Germany

Address

627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560

Website

https://www.nighthawkbio.com

NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.

Executives

Prendergast John K A	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf	director, officer: Chief Executive Officer	3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii	director	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander	officer: CFO/Corp Secy	801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan	director
Robert James Jakobs	officer: VP Finance/Controller/Secty	PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins	officer: Chief Scientific Officer	15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar	officer: VP of Finance and Controller	C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov	director	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech	officer: Chief Financial Officer	C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber	officer: Vice President of Research	100 EUROPA DRIVE, CHAPEL HILL NC 27517